Global languages
2022-05-10
Regulatory

Strong start to the year Favorable development in the Americas

Organic sales growth:
Q1, 2022: 15% (7)

EBITDA margin:
Q1, 2022: 36% (34)

1 January-31 March 2022

  • Net sales increased by 21% to SEK 162 million (134).
  • Sales increased organically by 15% (7), currency effect 6 %.
  • EBITDA amounted to SEK 59 million (46).
  • EBITDA margin amounted to 36% (34).
  • Profit before tax amounted to SEK 49 million (36).
  • Earnings per share before and after dilution were SEK 1.61 (1.19).
  • Cash flow from operating activities amounted to SEK 38 million (26).

Contact

Adele Horn
Corporate Communications & Investor Relations
Direct: +46 (0) 464 602 604
Mobile: +46 (0) 722 065 088

About Us

CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company´s 17 local market support organizations covering more than 40 countries. In 2021, sales were SEK 566 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

This information is information that CellaVision is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-05-10 07:20 CEST.

Attachments

Interim Report Q1 2022

Share